The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

Pediatric patients aged 10 years and older with iron deficiency may now be treated with Accrufer following an expanded FDA approval.

(HealthDay News) — The US Food and Drug Administration (FDA) is weighing a change that could make warning labels on dietary supplements appear less often on packaging. Unlike prescription drugs, ...

Veligrotug, an IGF-1R inhibitor, is under FDA Priority Review for thyroid eye disease based on positive phase 3 trial data.

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Vaccination linked to lower risk for hospitalization, critical care unit admission, preterm birth during delta and omicron periods ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.